The Application and Progress of Immune Checkpoint Inhibitors in the Immunotherapy of Non-Small Cell Lung Cancer
Received Date: Mar 23, 2022 / Accepted Date: Apr 07, 2022 / Published Date: Apr 08, 2022
Abstract
For several years now, the therapeutic situation in the management of non-small cell lung cancer using the immunotherapy protocol has allowed the approval of several drugs. These different drugs have shown fantastic results but with the downside of some side effects whether in monotherapy or in dual therapy with chemotherapy or radiotherapy.
The aim of our work was to review the different drugs administered in first- or second-line therapy for non-smallcell lung cancer and other drugs that are still in clinical research or have been dropped. In view of all this, the vaccine is being considered, but its application is still very much in doubt in the scientific community.
Citation: Hui DP, Joanes HGK, Wang ZX, Li L, Lu M (2022) The Application and Progress of Immune Checkpoint Inhibitors in the Immunotherapy of Non-Small Cell Lung Cancer. Int J Inflam Cancer Integr Ther, 9: 185. Doi: 10.4172/2381-8727.1000185
Copyright: © 2022 Hui DP. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Share This Article
Recommended Journals
Open Access Journals
Article Tools
Article Usage
- Total views: 1651
- [From(publication date): 0-2022 - Feb 04, 2025]
- Breakdown by view type
- HTML page views: 1311
- PDF downloads: 340
